* PayPal Holdings Inc is expected to show a rise in quarterly revenue when it reports results on February 10. * The San Jose California-based company is expected to report a 6.8% increase in revenue to $7.391 billion from $6.92 billion a year ago, according to the mean estimate from 35 analysts, based on Refinitiv data. The company's guidance on November 3 2022, for the period ended December 31, was for revenue of $7.471 billion. * Refinitiv's mean analyst estimate for PayPal Holdings Inc is for earnings of $1.20 per share. The company's EPS guidance on November 3 2022, for the period ended December 31, was between $1.18 and $1.20 * The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 38 "strong buy" or "buy," 11 "hold" and 1 "sell" or "strong sell." * The mean earnings estimate of analysts was unchanged in the last three months. * Wall Street's median 12-month price target for PayPal Holdings Inc is $100, above its last closing price of $83.23. The company's guidance on November 3 2022 for the period ended December 31 was for Earnings before Interest and Taxes of USD1.681074 billion. Previous quarterly performance (using preferred earnings measure in US dollars). QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI ENDING ARTESTIMAT IBES MET, SE % E® ESTIMATE MISSED Sep. 30 2022 0.96 0.96 1.08 Beat 12.7 Jun. 30 2022 0.86 0.86 0.93 Beat 8.2 Mar. 31 2022 0.88 0.88 0.88 Met 0.3 Dec. 31 2021 1.12 1.12 1.11 Missed -1.1 Sep. 1.08 1.07 1.11 Beat 3.5 30 2021 Jun. 30 2021 1.13 1.12 1.15 Beat 2.5 Mar. 31 2021 1.03 1.01 1.22 Beat 20.3 Dec. 31 2020 1.01 1.00 1.08 Beat 8.2 This summary was machine generated February 8 at 02:45 GMT. All figures in US dollars unless otherwise stated.
PayPal Holdings Inc expected to post earnings of $1.20 a share - Earnings Preview
The above content is directly sourced from Reuters under a contractual arrangement. The content is being provided as a convenience and for informational purposes only; and does not constitute an endorsement or approval by Kalkine Media of any of the products, services, or opinions of the organization or individual. The user is apprised that Kalkine Media bears no responsibility for the accuracy, legality, or content of Reuters, any external sites, or for that of subsequent links. The user is requested to contact Reuters directly for answers to questions regarding the content. Please note that Kalkine Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
89Bio's NASH drug meets main goals of mid-stage study
- March 22, 2023 04:30 AM PDT
Opera Goes Live With Generative AI Tools In Desktop Browser And Opera GX
- March 22, 2023 04:27 AM PDT
US FDA expands use of Regeneron's cholesterol drug in young children
- March 22, 2023 04:26 AM PDT